CRISPR | Cas9 Tools – Global Market and Patent Landscape Report till 2025
- The global markets for CRISPR-Cas9 genome editing were estimated at $1.22 billion in 2017. It is expected to reach $5.3 billion by 2025 growing at a CAGR of 20.19 per cent.
- With the USFDA announcement of CRISPR-Cas9 edited crops being treated as non-GMOs, in 2025 the application segment is expected to grow by four times of its market size in 2017.
- Clinical therapy segment is the leading focus area of R&D with 482 patent applications.
- Massachusetts Institute of Technology (MIT) holds the largest patent portfolio in CRISPR-Cas9 technology with 103 IP assets.
$600.00 – $3,900.00
- Table of Content
- Companies Profiled
- Analyst Review
- Request a Sample
- Contact Analyst
- What do you get when you purchase this report?
CRISPR | Cas9 Tools – Global Market and Patent Landscape Report till 2025 by Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal and disease model), by Products (editing tools, cell lines, animal models and plant breeding products), by Technology (drug compound and target screening, and agriculture and industrial use), by Patent Activities (patent categories and classification, leading patent players, technical analysis of patent landscape, patent licensing and litigation) – Global Forecast, 2025.
Executive Summary – CRISPR | Cas9 Tools – Global Market and Patent Landscape Report till 2025
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein-9 nuclease (Cas9) is an innovative genome editing tool that has recently transformed the arena of human genetic engineering. CRISPR/Cas9 can modulate gene expression in plants, humans, and animals based on an RNA-guided mechanism. The CRISPR/Cas9 programmable nucleases are the preferred choices over traditional genome editing technologies, which is attributable to ease in target design, the facility to target multiple sites in one step, and predictable off-target sites. The global markets for CRISPR-Cas9 genome editing were estimated at $1.22 billion in 2017. It is expected to reach $5.3 billion by 2025 growing at a CAGR of 20.19 per cent.
The technique is being effectively employed in therapeutics development, and research and design tools. Large biotech companies like Millipore Sigma (earlier Sigma Aldrich), Thermo Fisher Scientific, Toolgen, Genecopeia, Horizon Discovery, and Agilent Technologies and pharmaceuticals like Novartis, Vertex, Bayer AG, AstraZeneca, Evolva, Juno Therapeutics, and GE Healthcare have skin in the CRISPR game exploring novel techniques to evolve their drug discovery and development processes. They are forming strategic alliances with crucial CRISPR technology companies like Crispr Therapeutics, Editas Medicine, Caribou Biosciences and Intellia Therapeutics to devise gene-based therapies for various genetic diseases.
As the research and development investment in the technology is growing by leaps and bounds, the technology’s potential has been explored in newer areas of animal and disease model development, drug compound and target screening, and agriculture and nutritional health products. The ambidexterity of the CRISPR/Cas9 system in locating and altering specific genes is assisting researchers and scientists in understanding diseases using cells and animal models. Cas9 system has helped in achieving significant advancements in drug discovery and precluding genetic as well as cardiovascular diseases in humans. Novel treatments for single-gene disorders such as cystic fibrosis, haemophilia and sickle cell disease are being researched using Cas9 tools. This technique is anticipated to be useful in the prevention and cure of complex conditions, such as cancer, heart disease, mental illness, and human immunodeficiency virus (HIV) infection.
In 2017, the global CRISPR-Cas9 mediated drug discovery and development market are expected to jump to $1,305 million by 2020 and further grow by a CAGR of 23.8 per cent over a period of eight years from 2017 to 2025. The technology has the potential to develop genuinely personalized treatments and therapeutic medicines. The Clinical therapy market is expected to contribute significantly to the overall CRISPR-Cas9 tools market by 2025.
CRISPR-Cas9 tools will play a multifarious role in agriculture by enabling the industry in editing crops to make them more nutritious, enhanced taste, disease resistant, and less susceptible to drought. Agriculture and plant breeding application segment is restricted in growth by several potential regulatory requirements and ethical apprehensions. Established agritechs like DowDuPont, Monsanto, Syngenta, and new entrants like Pairwise are also extensively active in the CRISPR landscape. Industrial biotechnology and animal biotechnology together will contribute modestly to the global CRISPR-Cas9 genome editing market
Product type-based market segments include editing tools, cell lines, animal models, and plant breeding products. Regional-based market segments include North America, Europe, APAC and the Rest of World (RoW). The North American market has the maximum number of companies dealing with CRISPR-Cas9 products or services. The Chinese government is heavily committed to CRISPR research and has awarded more than 23 million yuan ($3.5 million) to 42 CRISPR projects.
CRISPR-Cas9 patent landscape is dominated by universities and research institutes over commercial companies. Out of the top 15 patent owners in the CRISPR-Cas9 patent space, companies represent approximately 40 per cent while five universities and four research institutes rank among the top 15 owners. US and Chinese academic institutions are actively pursuing research activities in CRISPR domain.
Table of Content
About Ahead Intel (Page no. – 1)
Disclaimer (Page no. – 2)
Executive Summary (Page no. – 3)
- Introduction (Page no. – 6)
1.1 Reasons For The Study
1.2 Study Goals and Objectives
1.3 Scope Of The Report
1.4 Methodology and Information Sources
1.5 Intended Audience
Technology Landscape (Page no. – 9)
2.1 Introduction To Crispr-Cas9 System
2.2 Discovery Of Crispr-Cas9
2.3 Historical Events In Crispr-Cas9 Technology
2.4 Components Of Crispr-Cas9 Systems
2.5 Crispr-Cas9 Immunity Mechanism
2.6 Crispr-Cas9 Delivery System
2.6.1 Physical Delivery Methods.
2.6.2 Viral Vector Delivery Methods.
2.6.3 Non-Viral Vector Delivery Methods.
Business Landscape And Forecast (Page no. – 20)
3.1 Crispr-Cas9 Market Segmentation and Forecast
3.1.1 Market Overview
3.1.2 Major Players
3.1.3 Distribution Of Companies By Region
3.1.4 Market Segmentation By Region
3.1.5 Market Segmentation By Application
3.1.6 Market Segmentation By Product
3.2 Market Drivers
3.2.1 Advantages Over Competing Technologies
3.2.2 High Investments By Private Equity Firms And Venture Capitalists.
3.2.3 Growing Application Areas.
3.2.4 Expanding Market Of Genetically Modified Crops.
3.2.5 Increasing Global Burden Of Cancer, Cardiovascular Diseases and Infectious Diseases.
3.3 Market Restraints.
3.3.1 Challenges In Accuracy Of Cas9 Tools.
3.3.2 Difficulties With The Delivery Of Cas9 Into Tissues Or Cells.
3.3.3 Ethical Issues From Misuse Of Gene-Editing Tools.
3.3.4 Secure Storage Of Large Volumes Of Sequenced Data.
3.4 Crispr-Cas9 Market Segmentation By Application.
3.4.2 Academic Research Market: Trend Analysis And Forecasts.
3.4.3 Drug Discovery And Development Market: Trend Analysis And Forecasts.
3.4.4 Clinical Therapy Market: Trend Analysis And Forecasts.
3.4.5 Agriculture And Plant Breeding Market: Trend Analysis And Forecasts.
3.4.6 Industrial Biotechnology Market: Trend Analysis and Forecasts.
3.4.7 Animal Biotechnology Market: Trend Analysis And Forecasts.
3.5 Crispr-Cas9 Tools Market Segmentation By Product Type.
3.5.1 Product Overview
3.5.2 Product Market Forecast
Competitive Landscape And Opportunities (Page no. – 103)
4.1 Competitive Environment
4.2 Growth Strategies.
4.2.1 Academic And Corporate Collaborations.
4.2.2 Innovation Start Ups.
4.2.3 Strategic Alliances And Joint Ventures.
4.2.4 Venture Capital Funding.
4.3 Opportunity Matrix.
4.4 Strategic Imperatives.
Active Companies (Page no. – 111)
5.2 Agilent Technologies Inc.
5.3 Applied Biological Materials Inc.
5.4 Atum (Formerly Dna2.0)
5.5 Caribou Biosciences
5.6 Casebia Therapeutics
5.7 Crispr Therapeutics
5.8 Editas Medicine
5.11 Horizon Discovery (Dharmacon)
5.12 Intellia Therapeutics
5.13 New England Biolabs
5.14 Origene Technologies Inc
5.15 Sigma Aldrich (Acquired By Merck)
5.16 System Biosciences
5.17 Takara Bio Usa, Inc. (Formerly Clontech Laboratories)
5.18 Thermo Fisher Scientific
5.19 Toolgen Inc.
5.20 Transposagen Biopharmaceutical
Innovation Landscape (Page no. – 147)
6.2 Search Strategy
6.3 Categories And Cpc Classification
6.4 How Is The Innovation Activity Trend?
6.5 What Are The Key Grant Timelines?
6.6 Who Are The Leading Players?
6.6.1 Who Is Making Substantial Investment In The Technology?
6.6.2 Who Are The Key Inventors In The Domain?
6.6.3 Who Is More Active In? Academia Or Corporate?
6.6.4 Are There Collaboration Networks?
6.7 Which Are The Current Technological Focus Areas?
6.7.1 Which Application Area Will Drive R&D Market?
6.7.2 Which Product Type Is Gaining Momentum?
6.7.3 Which Are The Key Geographies For Setting Up Innovation Centers?
6.7.4 Which Geographies Are Touted As Investment Goldmines?
6.8 Patent Licensing And Litigation.
6.8.1 Is The Technology Being Licensed?
6.8.2 Litigation Issues Affecting Commercialization.
6.8.3 Did Any Ip Acquisition Happen?
6.9 Regulatory Framework.
- Appendix. (Page no. – 182)
7.1 Acronyms and Abbreviations.
7.2 Analyst Profile.
- Table Of Tables
Table 1: Timeline For Development Of Crispr-Cas9 Technology.
Table 2: Key Companies With Commercial Interest In Crispr-Cas9 Technology.
Table 3: Distribution Of Companies With Crispr-Cas9 Genome Editing Related Businesses By Region, As Of May 2018.
Table 4: Global Markets For Crispr-Cas9 Genome Editing, Through 2025. 24
Table 5: Global Markets For Crispr-Cas9 Genome Editing, By Application Segment Through 2025. 28
Table 6: North American Markets For Crispr-Cas9 Genome Editing, By Application Segment, 2017-2025 31
Table 7: European Markets For Crispr-Cas9 Genome Editing, By Application Segment, 2017-2025. 32
Table 8: Apac Markets For Crispr-Cas9 Genome Editing, By Application Segment, 2017-2025. 33
Table 9: Row Markets For Crispr-Cas9 Genome Editing, By Application Segment, 2017-2025. 33
Table 10: Global Market For Crispr-Cas9 Genome Editing By Product Type, Through 2025. 35
Table 11: Comparative Advantage Of Crispr-Cas9 Over Other Critical Competing Technologies.
Table 12: Global Markets For Crispr-Cas9 Genome Editing By Academic Research Application, Through 2025
Table 13: Global Crispr-Cas9 Collaborations In Drug Discovery And Development Market.
Table 14: Global Markets For Crispr-Cas9 Genome Editing By Drug Discovery And Development Application, Through 2025.
Table 15: Global Crispr-Cas9 Collaborations In Clinical Therapy Market.
Table 16: Global Markets For Crispr-Cas9 Genome Editing, By Clinical Therapy Application, Through 2025 68
Table 17: Crispr-Cas9 Research Experiments In Agriculture And Plant Breeding.
Table 18: Global Crispr-Cas9 Collaborations In Agriculture And Plant Breeding Market.
Table 19: Global Markets For Crispr-Cas9 Genome Editing By Agriculture And Plant Breeding Application, Through 2025.
Table 20: Global Markets For Crispr-Cas9 Genome Editing By Industrial Biotechnology Application, Through 2025.
Table 21: Global Crispr-Cas9 Collaborations In Animal Biotechnolgy Market.
Table 22: Global Markets For Crispr-Cas9 Genome Editing By Animal Biotechnology Application, Through 2025
Table 23: Companies Providing Cas9 Enzymes And Protein Products.
Table 24: Companies Providing Expression Plasmid And Viral Vector Products.
Table 25: Companies Providing Sgrna Products.
Table 26: Companies Providing Mrna Products.
Table 27: Companies Providing Delivery Reagents And Other Accessory Reagents.
Table 28: Companies Providing Cas9 Stable Cell Lines Products.
Table 29: Global Markets For Crispr-Cas9 Genome Editing By Product Type, Through 2025.
Table 30: North America Market For Crispr-Cas9 Genome Editing By Product Type, Through 2025.
Table 31: European Market For Crispr-Cas9 Genome Editing By Product Type, Through 2025.
Table 32: Apac Market For Crispr-Cas9 Genome Editing By Product Type, Through 2025.
Table 33: Row Market For Crispr-Cas9 Genome Editing By Product Type, Through 2025.
Table 34: Innovative Crispr-Cas9 Genome Editing Start Ups.
Table 35: Crispr-Related Scientific Publications, 2001 To 2016.
Table 36: Early Filings In Crispr-Cas9.
Table 37: Grant Timelines In Crispr-Cas9 Landscape.
Table 38: Innovation Timeline For Top 15 Patent Owners In Crispr-Cas9 Technology.
Table 39: Patent Categories For Crispr-Cas9 Technology Landscape.
Table 40: Patent Portfolio Of Top 15 Assignees Across Application Segmentation.
Table 41: Level 2 and Level 3 Product Type Categories With The Number Of Patents.
Table 42: Patent Portfolio Of Top 20 Assignees Across Level 2 And Level 3 Product Type Segmentation
Table 43: Number And Evolution Of Patent Families Per Office Of First Filling.
9.Table Of Figures
Figure 1: Crispr Immunity Mechanism In Bacteria And Archaea. 14
Figure 2: Crispr-Cas9 Dna Cleavage Activity.
Figure 3: Distribution Of Companies With Crispr-Cas9 Genome Editing Related Businesses By Region, As Of May 2018.
Figure 4: Global Markets For Crispr-Cas9 Genome Editing, 2017-2025 (In $ Million)
Figure 5: Global Crispr-Cas9 Genome Editing Market Share By Region, 2017 (Percentage)
Figure 6: Global Crispr-Cas9 Genome Editing Market Share By Region, 2025 (Percentage)
Figure 7: Global Markets For Crispr-Cas9 Genome Editing, By Application Segments, 2017-2025 (In $ Million)
Figure 8: Global Crispr-Cas9 Genome Editing Market Share By Application, 2017 (Percentage)
Figure 9: Global Crispr-Cas9 Genome Editing Market Share By Application, 2025 (Percentage)
Figure 10: Global Market For Crispr-Cas9 By Product Type (In $ Million), 2017 To 2025.
Figure 11: Global Market Share For Crispr-Cas9 Genome Editing By Product Type, 2017 And 2025 (In Percentage)
Figure 12: Global Markets For Crispr-Cas9 Genome Editing By Academic Research Application, Through 2025 ($Millions)
Figure 13: Global Markets For Crispr-Cas9 Genome Editing By Academic Research Application, Percentage Share, 2017 And 2025.
Figure 14: Drug Discovery Cycle.
Figure 15: Global Markets For Crispr-Cas9 Genome Editing By Drug Discovery And Development Application, Through 2025.
Figure 16: Global Crispr-Cas9 Drug Discovery And Development Market By Region (Percentage)
Figure 17: Global Markets For Crispr-Cas9 Genome Editing By Clinical Therapy Application, Through 2025
Figure 18: Global Crispr-Cas9 Clinical Therapy Application Market By Region (Percentage)
Figure 19: Global Markets For Crispr-Cas9 Genome Editing By Agriculture And Plant Breeding Application, Through 2025.
Figure 20: Global Crispr-Cas9 Agriculture And Plant Breeding Application Market By Region (Percentage) 76
Figure 21: Global Markets For Crispr-Cas9 Genome Editing By Industrial Biotechnology Application, Through 2025.
Figure 22: Global Crispr-Cas9 Industrial Biotechnology Application Market By Region (Percentage)
Figure 23: Global Markets For Crispr-Cas9 Genome Editing By Animal Biotechnology Application, Through 2025
Figure 24: Global Crispr-Cas9 Animal Biotechnology Application Market By Region (Percentage)
Figure 25: Crispr-Cas9 Tools Market Segmentation By Product Type.
Figure 26: Global Markets For Crispr-Cas9 Genome Editing By Product Type, Through 2025.
Figure 27: Global Crispr-Cas9 Animal Biotechnology Product Market By Region (Percentage)
Figure 28: Global Growth Opportunity Matrix For Crispr-Cas9 Application.
Figure 29 Schematic Diagram To Represent Key Steps In Patent Analysis Process.
Figure 30: Thematic Concept Map For Crispr-Cas9 Genome Editing.
Figure 31: Top 10 Cpc Classification Categories For Crispr-Cas9 Landscape.
Figure 32: Global Crispr-Cas9 Patenting Activity Trend.
Figure 33: Top 15 Patent Owners In The Crispr-Cas9 Patent Landscape.
Figure 34: Top 20 Inventors In The Crispr-Cas9 Patent Landscape.
Figure 35: Analysis Of Patent Applicant Profile.
Figure 36: Collaboration Networks-Co-Assignment.
Figure 37: Global Crispr-Cas9 Patenting Trends Based On Application Areas (2008-2018).
Figure 38: Major Offices Of First Fillings Linked To Their Region.
Figure 39: Geographic Map Of R&D In The Field Of Crispr-Cas9 Technology.
Figure 40: Geographic Map Of Market Opportunities In Crispr-Cas9 Technology.
Figure 41: Representation Of Market Opportunities From Crispr-Cas9 Patent Landscape.
Figure 42: License Tree For Crispr-Cas9 Patent Landscape.
List of companies profiled in the report.
- Agilent Technologies Inc.
- Applied Biological Materials Inc
- ATUM (formerly DNA2.0)
- Caribou Biosciences
- Casebia Therapeutics
- Crispr Therapeutics
- Editas Medicine
- Horizon Discovery (Dharmacon)
- Intellia Therapeutics
- New England Biolabs
- Origene Technologies Inc.
- Sigma Aldrich (acquired by Merck)
- System Biosciences
- Takara Bio USA, Inc. (formerly Clontech Laboratories)
- Thermo Fisher Scientific
- Toolgen Inc.
- Transposagen Biopharmaceutical
Crispr-Cas9 research study aims at analyzing the current market dynamics and prospective future developments to present an accurate business and patent landscape for CRISPR-Cas9 technology.
This report focuses on the CRISPR-Cas9 genome editing tools including its technology, market, and patent landscape. CRISPR-Cas9 market is further segmented by applications into academic research tools, drug development, agriculture, human clinical therapeutics, and animal and disease model; by products into editing tools, cell lines, animal models, and plant breeding products; and by regional segmentation into North America, Europe, Asia Pacific (APAC) and Rest of World (RoW). The report forecasts the sizes and trends of the global market as well as its sub-segments for the period 2018 to 2025. The report focuses on critical market segments to identify the key market and technology trends. Market driving factors and constraints have been considered to estimate global CRISPR-Cas9 market potential.
Patent trends have been presented in detail to understand the research and development activities happening around the world over the years. The study also delves into licensing and litigation battles which are restricting the commercial growth of the market. The report will also present a competitive landscape focusing on active players in the industry, growth strategies, strategic imperatives and detailed profiling of critical companies.
Gene-editing tools based on CRISPR-Cas9 have applicability not just in human therapeutics and drug development but have also demonstrated compelling results in animal biotechnology, plant and agriculture gene editing, and industrial biotechnology applications. It is primarily based on the multiple gene indels possible with CRISPR-Cas9.Along with thousands of research laboratories working on CRISPR globally, significant players in the field of CRISPR-Cas9 genome editing also include life science tools companies that have added CRISPR-Cas9 editing tools to their product portfolio or provide custom services like cell line creation, gRNA cloning etc. CRISPR-Cas9 is a revolutionary gene editing tool whose effectiveness and ease of use has fast-tracked innovation beyond traditional industries. It has served as the foundation for several biotech startup companies to flourish commercially like Mammoth Biosciences, Agenovir Corporation, eGenesis, Plantedit, NTrans Technologies, and Beam therapeutics.
The crispr-cas9 landscape is inundated with strategic partnerships which have become a core component of growth strategies being employed by several CRISPR tool companies, biopharma companies, academic centres, universities and other relevant organisations. The growing potential of CRISPR-Cas9 gene editing is additionally reflected in the exponential increase in CRISPR related federal research funding and scientific publications. Since 2013, leading CRISPR-Cas9 companies have received over $800 million in venture capital and public market investments.
Even with the huge potential of the technology, benefit realization is still at an embryonic stage owing to the ethical issues of ecological disequilibrium, gene editing for non-therapeutic interventions, and bio attacks. Leading players should endeavor to assist the global governments to develop standardized regulatory norms to further ensure appropriate advancement of this ground-breaking technology.
Request a Sample
What do you get when you purchase this report?
Our full offer includes a Report + Access to an IP Intelligence Dashboard as per the details below:
- 43 market data tables and 42 figures in a 185 page up to date report on CRISPR Cas9 Tools Market and Patent Landscape. The Report includes:
- Analysis by
- Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal and disease model)
- Products (editing tools, cell lines, animal models and plant breeding products)
- Technology (drug compound and target screening, and agriculture and industrial use)
- Leading companies profiled – 20
- Patent Activities (patent categories and classification, leading patent players, technical analysis of patent landscape)
- Exclusive research on Patent licensing, IP acquisition, Litigation and Commercialization
- Global Forecast till 2025
- A 1 year access to an on-line access to an interactive IP intelligence dashboard with full details of the patent data behind the report where you can:
- Review the most important patents in the space and download their PDFs
- View Patent information categorized as per the taxonomy mentioned in the report
- View overall technology trends against companies, inventors and their research
- Identify most active competitors and understand their strategies
- Identify key (prolific) inventors within a particular organization or technology space
- Identify new application areas of the technologies involved
- Identify new licensing and research opportunities
- Identify patent/company acquisition opportunities